Matrix composition for transdermal therapeutic system

Details Matrix composition for transdermal therapeutic system Matrix composition for transdermal therapeutic system

1983-05-04

1985-12-17

Rose, Shep K.

Drug, bio-affecting and body treating compositions

Solid synthetic organic polymer as designated organic active...

Polymer from ethylenic monomers only

424 22, 424 83, 514770, A61F 1300, A61L 1503, A61K 970, A61K 31745

Patent

active

045592225

ABSTRACT:
Mineral oil (MO) polyisobutylene (PIB), colloidal silicon dioxide (CSD) mixtures suitable for use as drug containing matrices in transdermal delivery systems are disclosed. Preferred systems for dispensing moderately mineral oil soluble drugs contain at least about 6% CSD, have a MO/PIB of at least 1.0 and a viscosity of at least 1.5.times.10.sup.7 poises. Preferred systems for dispensing clonidine have a clonidine permeability of at least 1.0.times.10.sup.-4 .mu.g/cm sec and a MO/PIB of at least 1.2.

REFERENCES:
patent: 2627938 (1953-02-01), Frohmader et al.
patent: 2628205 (1953-02-01), Shoemaker
patent: 2775561 (1956-12-01), Frohmader
patent: 3029188 (1962-04-01), Cyr et al.
patent: 3079299 (1963-02-01), Heilig
patent: 3215599 (1965-11-01), Thau et al.
patent: 3250680 (1966-05-01), Menkart et al.
patent: 3293205 (1966-12-01), Doyle et al.
patent: 3400197 (1968-09-01), Lippmann
patent: 3574827 (1971-04-01), Beerbower
patent: 3733403 (1973-05-01), Chen

Affiliated with

Also associated with

Rating

Matrix composition for transdermal therapeutic system does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Matrix composition for transdermal therapeutic system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Matrix composition for transdermal therapeutic system will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2174200